SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
A Young Sim, Jong Youl Kim, Yong-ho Lee, Jong Eun Lee · FENS Forum 2024
Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common features, including insulin resistance. Brain insulin resistance has been implicated as a key factor in the pathogenesis of AD. Recent studies have demonstrated that sodium–glucose cotransporter-2 inhibitor (SGLT2-i) and dipeptidyl peptidase-4 inhibitor (DPP4-i) improve insulin sensitivity and provide neuroprotection. However, the effects of these two inhibitors on the brain metabolism and insulin resistance remain uninvestigated.We developed a T2D–AD mouse model using a high-fat diet (HFD) for 19 weeks along with a single dose of
ePoster · Neuroscience